{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:08Z","timestamp":1792827848074,"version":"4.5.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024749","name":"National Institute for Health and Care Research Applied Research Collaboration North East and North Cumbria","doi-asserted-by":"publisher","award":["NIHR200173"],"award-info":[{"award-number":["NIHR200173"]}],"id":[{"id":"10.13039\/501100024749","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Thyrotropin (TSH) levels tend to rise with age, but standard reference intervals do not reflect this, potentially leading to overdiagnosis of subclinical hypothyroidism (SCH) and excessive levothyroxine (LT4) prescriptions in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to compare outcomes in adults older than 50 years with SCH who were either prescribed or not prescribed LT4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using data from UK Primary Care patients from the Health Improvement Network. The primary outcome was cardiovascular (CV) events (angina, myocardial infarction, peripheral vascular disease, stent procedures, or stroke). Secondary outcomes included bone events (fragility fractures or osteoporosis) and all-cause mortality. Time-varying hazard ratios (HRs) adjusted for relevant factors were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 53 899 patients (baseline median age 67 years (interquartile range [IQR]: 59-76 years); 68.5% female; median TSH 4.6\u2005mU\/L (IQR: 4.1-5.4 mU\/L). Median follow-up duration was 10 years (IQR: 5.5-10.0 years). Of these, 19 952 (37%) received LT4 and 33 947 (63%) did not. LT4 therapy showed a protective effect against CV events (HR: 0.91; 95% CI, 0.87-0.97; P &amp;lt; .001) but increased risk of bone events (HR: 1.21; 95% CI, 1.14-1.28; P &amp;lt; .001) and all-cause mortality (HR: 1.17; 95% CI, 1.13-1.22; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data suggest that LT4 therapy in older individuals with SCH is associated with a trade-off between the potentially beneficial effect on CV risk and the deleterious relationship with bone health and mortality risk. These risks need to be considered, mitigated, and discussed when LT4 therapy is being deliberated in older patients with SCH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf208","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T10:36:02Z","timestamp":1743590162000},"page":"e4137-e4143","source":"Crossref","is-referenced-by-count":10,"title":["Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-6314","authenticated-orcid":false,"given":"Mia","family":"Holley","sequence":"first","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland , Sunderland SR1 3SD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-1556","authenticated-orcid":false,"given":"Salman","family":"Razvi","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle-upon-Tyne NE1 3BZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9506-7157","authenticated-orcid":false,"given":"Ian","family":"Maxwell","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland , Sunderland SR1 3SD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-1724","authenticated-orcid":false,"given":"Rosie","family":"Dew","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland , Sunderland SR1 3SD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-7711","authenticated-orcid":false,"given":"Scott","family":"Wilkes","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland , Sunderland SR1 3SD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"9821","key":"2025111718524060100_dgaf208-B1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(11)60276-6","article-title":"Subclinical thyroid disease","volume":"379","author":"Cooper","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"2025111718524060100_dgaf208-B2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cen.12824","article-title":"Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee","volume":"84","author":"Okosieme","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025111718524060100_dgaf208-B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2265.2007.03051.x","article-title":"Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS)","volume":"68","author":"Leese","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025111718524060100_dgaf208-B4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111718524060100_dgaf208-B5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2265.1991.tb01739.x","article-title":"Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom","volume":"34","author":"Parle","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025111718524060100_dgaf208-B6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-8587(21)00285-0","article-title":"Subclinical hypothyroidism in older individuals","volume":"10","author":"Biondi","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2025111718524060100_dgaf208-B7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/jc.2012-3191","article-title":"Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the thyroid epidemiology, audit, and research study (TEARS)","volume":"98","author":"Vadiveloo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025111718524060100_dgaf208-B8","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1210\/jc.2012-2481","article-title":"Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study","volume":"97","author":"Waring","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025111718524060100_dgaf208-B9","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1210\/jc.2011-3020","article-title":"Age-related changes in thyroid function: a longitudinal study of a community-based cohort","volume":"97","author":"Bremner","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025111718524060100_dgaf208-B10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1089\/thy.2016.0133","article-title":"Thyroid function characteristics and determinants: the Rotterdam study","volume":"26","author":"Chaker","year":"2016","journal-title":"Thyroid\u00ae"},{"issue":"21","key":"2025111718524060100_dgaf208-B11","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1001\/archinte.165.21.2460","article-title":"Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death","volume":"165","author":"Rodondi","year":"2005","journal-title":"Arch Intern Med"},{"issue":"21","key":"2025111718524060100_dgaf208-B12","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1001\/archinternmed.2009.392","article-title":"Subclinical hypothyroidism and functional mobility in older adults","volume":"169","author":"Simonsick","year":"2009","journal-title":"Arch Intern Med"},{"issue":"4","key":"2025111718524060100_dgaf208-B13","first-page":"e14296","article-title":"Subclinical hypothyroidism in geriatric population and its association with heart failure","volume":"13","author":"Panday","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"2025111718524060100_dgaf208-B14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1871530311313010003","article-title":"Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies","volume":"13","author":"Gencer","year":"2013","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"21","key":"2025111718524060100_dgaf208-B15","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1001\/jama.292.21.2591","article-title":"Thyroid status, disability and cognitive function, and survival in old age","volume":"292","author":"Gussekloo","year":"2004","journal-title":"JAMA"},{"key":"2025111718524060100_dgaf208-B16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/CIA.S23966","article-title":"Hypothyroidism in the elderly: diagnosis and management","volume":"7","author":"Bensenor","year":"2012","journal-title":"Clin Interv Aging"},{"issue":"3","key":"2025111718524060100_dgaf208-B17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/er.2013-1083","article-title":"Treatment with thyroid hormone","volume":"35","author":"Biondi","year":"2014","journal-title":"Endocr Rev"},{"issue":"1","key":"2025111718524060100_dgaf208-B18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1210\/er.2006-0043","article-title":"The clinical significance of subclinical thyroid dysfunction","volume":"29","author":"Biondi","year":"2008","journal-title":"Endocr Rev"},{"issue":"1","key":"2025111718524060100_dgaf208-B19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2009-1625","article-title":"Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy","volume":"95","author":"Flynn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111718524060100_dgaf208-B20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2013.11312","article-title":"Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study","volume":"174","author":"Taylor","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2025111718524060100_dgaf208-B21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000356507","article-title":"2013 ETA guideline: management of subclinical hypothyroidism","volume":"2","author":"Pearce","year":"2013","journal-title":"Eur Thyroid J"},{"issue":"10","key":"2025111718524060100_dgaf208-B22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/archinternmed.2012.1159","article-title":"Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality","volume":"172","author":"Razvi","year":"2012","journal-title":"Arch Intern Med"},{"issue":"14","key":"2025111718524060100_dgaf208-B23","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1056\/NEJMc1709989","article-title":"Thyroid hormone therapy for older adults with subclinical hypothyroidism","volume":"377","author":"Ogunsakin","year":"2017","journal-title":"N Engl J Med"},{"key":"2025111718524060100_dgaf208-B24","doi-asserted-by":"crossref","first-page":"674841","DOI":"10.3389\/fendo.2021.674841","article-title":"Levothyroxine treatment and cardiovascular outcomes in older people with subclinical hypothyroidism: pooled individual results of two randomised controlled trials","volume":"12","author":"Zijlstra","year":"2021","journal-title":"Front. Endocrinol"},{"issue":"1","key":"2025111718524060100_dgaf208-B25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13643-024-02548-7","article-title":"Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis","volume":"13","author":"Holley","year":"2024","journal-title":"Syst Rev"},{"issue":"5","key":"2025111718524060100_dgaf208-B26","doi-asserted-by":"crossref","first-page":"e0268070","DOI":"10.1371\/journal.pone.0268070","article-title":"The impact of the management strategies for patients with subclinical hypothyroidism on long-term clinical outcomes: an umbrella review","volume":"17","author":"Bauer","year":"2022","journal-title":"PLoS One"},{"key":"2025111718524060100_dgaf208-B27"},{"issue":"1","key":"2025111718524060100_dgaf208-B28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13044-023-00186-0","article-title":"Assessing the cardiovascular effects of levothyroxine use in an ageing United Kingdom population (ACEL-UK) protocol: a cohort and target trial emulation study","volume":"16","author":"Holley","year":"2023","journal-title":"Thyroid Res"},{"issue":"1","key":"2025111718524060100_dgaf208-B29","doi-asserted-by":"crossref","first-page":"e29776","DOI":"10.1371\/journal.pone.0029776","article-title":"Coding, recording and incidence of different forms of coronary heart disease in primary care","volume":"7","author":"Bhattarai","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"2025111718524060100_dgaf208-B30","first-page":"188","article-title":"Charlson comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"2025111718524060100_dgaf208-B31","volume-title":"An Introduction to Medical Statistics","author":"Bland","year":"2015"},{"key":"2025111718524060100_dgaf208-B32","doi-asserted-by":"crossref","unstructured":"Holley M, Razvi S, Maxwell I, Dew R, Wilkes S. Supplementary Material for \u2018Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom population (ACEL-UK): Cohort Study\u2019 2025. Figshare. 10.6084\/m9.figshare.28472141.v2","DOI":"10.1210\/clinem\/dgaf208"},{"issue":"4","key":"2025111718524060100_dgaf208-B33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025111718524060100_dgaf208-B34","doi-asserted-by":"crossref","first-page":"l4892","DOI":"10.1136\/bmj.l4892","article-title":"Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study","volume":"366","author":"Thayakaran","year":"2019","journal-title":"BMJ"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf208\/62857179\/dgaf208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4137\/62857179\/dgaf208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/12\/e4137\/62857179\/dgaf208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:52:59Z","timestamp":1763423579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/12\/e4137\/8105666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,3]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf208","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,4,3]]}}}